<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004464</url>
  </required_header>
  <id_info>
    <org_study_id>J9611</org_study_id>
    <secondary_id>96-01-17-02</secondary_id>
    <secondary_id>JHOC-96011702</secondary_id>
    <secondary_id>JHOC-9611</secondary_id>
    <secondary_id>199/13895</secondary_id>
    <nct_id>NCT00004464</nct_id>
  </id_info>
  <brief_title>Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria</brief_title>
  <official_title>High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Confirm the efficacy demonstrated in a pilot study using high dose
      cyclophosphamide in patients with severe aplastic anemia.

      II. Determine whether the addition of filgrastim (G-CSF) to high dose cyclophosphamide
      shortens the time to recovery in these patients.

      III. Determine whether this regimen is efficacious in treating paroxysmal nocturnal
      hemoglobinuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients receive high dose cyclophosphamide IV on days 1-4. Beginning on
      day 10, patients receive filgrastim (G-CSF) until the absolute neutrophil count is greater
      than 1,000/mm3 for 2 consecutive days.

      Patients are followed every 3 months for at least 2 years and annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1996</start_date>
  <completion_date type="Actual">November 11, 2008</completion_date>
  <primary_completion_date type="Actual">March 1, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">69</enrollment>
  <condition>Aplastic Anemia</condition>
  <condition>Paroxysmal Hemoglobinuria, Nocturnal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Acquired severe aplastic anemia or paroxysmal nocturnal hemoglobinuria

          -  Not a candidate for allogeneic bone marrow transplantation

          -  Must meet one of the following criteria:

               -  Severe aplastic anemia

                    -  Less than 25% bone marrow cellularity and depression in two of three blood
                       counts (reticulocytes less than 40,000/mm3

                    -  platelet count less than 20,000/mm3 and granulocytes less than 500/mm3)

               -  Life-threatening paroxysmal nocturnal hemoglobinuria

                    -  Absolute neutrophil count less than 500/mm3

                    -  platelet transfusion dependent

                    -  thrombotic disease

          -  No Fanconi anemia

          -  No abnormal cytogenetics

        --Patient Characteristics--

          -  Renal: Creatinine no greater than 2.0 mg/dL

          -  Cardiovascular: Cardiac ejection fraction at least 45%

          -  Other: Not preterminal or moribund Not pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A. Brodsky</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aplastic anemia</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>paroxysmal nocturnal hemoglobinuria</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

